{"id":390764,"date":"2017-12-20T00:00:00","date_gmt":"2017-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0010-2017-biopharma-atopic-dermatitis-atopic-eczema-unmet-need-atopic-dermatitis-atopic-eczema-moderate-to-severe\/"},"modified":"2026-04-27T11:28:08","modified_gmt":"2026-04-27T11:28:08","slug":"unneim0010-2017-biopharma-atopic-dermatitis-atopic-eczema-unmet-need-atopic-dermatitis-atopic-eczema-moderate-to-severe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0010-2017-biopharma-atopic-dermatitis-atopic-eczema-unmet-need-atopic-dermatitis-atopic-eczema-moderate-to-severe\/","title":{"rendered":"Atopic Dermatitis\/Atopic Eczema | Unmet Need | Atopic Dermatitis\/Atopic Eczema &#8211; Moderate to Severe | US\/EU | 2017"},"content":{"rendered":"<p>The atopic dermatitis (AD) market is poised to undergo a revolution owing to recent advances in understanding of disease pathology, the recent approval of topical crisaborole (Pfizer\u2019s Eucrisa) in the United States, and the high-profile development of the first targeted AD biologic, dupilumab (Sanofi\/Regeneron\u2019s Dupixent). Although many treatments, both topical and systemic, are available for the treatment of atopic dermatitis, tremendous unmet need remains for therapies that treat severe, treatment-refractory atopic dermatitis. In this analysis, we assess the commercial opportunity that exists in the atopic dermatitis space through a comprehensive look at dermatologists\u2019 treatment goals; the key efficacy, safety, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the appeal of hypothetical new AD products.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for AD?<\/li>\n<li>What attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for AD?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in AD?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists\u00a0for a hypothetical new AD\u00a0drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60\u00a0U.S. and 30\u00a0European dermatologists\u00a0fielded in\u00a0January 2017<\/p>\n<p><strong>Key companies:<\/strong>\u00a0Pfizer, Sanofi, Regeneron, Valeant, Astellas<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Elidel, Eucrisa, Dupixent, Protopic<\/p>\n","protected":false},"template":"","class_list":["post-390764","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390764\/revisions"}],"predecessor-version":[{"id":393888,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390764\/revisions\/393888"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}